<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607111414714</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607111414714</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Bloodstream Infections Associated With Parenteral Nutrition Preparation Methods in the United States</article-title>
<subtitle>A Retrospective, Large Database Analysis</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western"><surname>Turpin</surname><given-names>Robin S.</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414714">1</xref>
<xref ref-type="aff" rid="aff2-0148607111414714">2</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Canada</surname><given-names>Todd</given-names></name>
<degrees>PharmD, BCNSP, FASHP</degrees>
<xref ref-type="aff" rid="aff3-0148607111414714">3</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Rosenthal</surname><given-names>Victor D.</given-names></name>
<degrees>MD, MSc, CIC</degrees>
<xref ref-type="aff" rid="aff4-0148607111414714">4</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Nitzki-George</surname><given-names>Diane</given-names></name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff5-0148607111414714">5</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Liu</surname><given-names>Frank Xiaoqing</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414714">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Mercaldi</surname><given-names>Catherine J.</given-names></name>
<degrees>MPH</degrees>
<xref ref-type="aff" rid="aff6-0148607111414714">6</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Pontes-Arruda</surname><given-names>Alessandro</given-names></name>
<degrees>MD, MSc, PhD, FCCM</degrees>
<xref ref-type="aff" rid="aff7-0148607111414714">7</xref>
<role>for the IMPROVE Study Group</role>
</contrib>
</contrib-group>
<aff id="aff1-0148607111414714"><label>1</label>Global Health Economics, Baxter Healthcare, Deerfield, Illinois</aff>
<aff id="aff2-0148607111414714"><label>2</label>Public Policy Department, Thomas Jefferson Hospital, Philadelphia, Pennsylvania</aff>
<aff id="aff3-0148607111414714"><label>3</label>University of Texas MD Anderson Cancer Center, Houston, Texas</aff>
<aff id="aff4-0148607111414714"><label>4</label>International Nosocomial Infection Control Consortium, Buenos Aires, Argentina</aff>
<aff id="aff5-0148607111414714"><label>5</label>NorthShore University Health System, Glenview, Illinois</aff>
<aff id="aff6-0148607111414714"><label>6</label>United Biosource Corporation, Lexington, Massachusetts</aff>
<aff id="aff7-0148607111414714"><label>7</label>Department of Nutrition and Intensive Care, Fernandes Távora Hospital, Fortaleza, Ceará, Brazil</aff>
<author-notes>
<corresp id="corresp1-0148607111414714">Robin S. Turpin, PhD, Global Health Economics, Baxter Healthcare, One Baxter Parkway, Deerfield, IL 60015; e-mail: <email xlink:type="simple">robin_turpin@baxter.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>176</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>2</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>4</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 The American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background:</italic> The incidence of bloodstream infection (BSI) among patients receiving parenteral nutrition (PN) is reported to vary widely from 1.3%−39%. BSI rates in a large inpatient population were compared in this study to determine if PN prepared by different methods was associated with BSI. <italic>Methods:</italic> Data from Premier Perspective, the largest inpatient cost-based clinical and financial claims database in the United States, were analyzed. Included were all hospitalized patients age ≥18 years who received any PN from January 1, 2005, to December 31, 2007. BSI rates, the primary dependent variable, were defined as the occurrence <italic>ICD-9</italic> codes of 038.x (septicemia), 995.91 (sepsis), 995.92 (severe sepsis), and 790.7 (bacteremia). The exposure cohort received PN in a commercial multichamber bag (MCB) (n = 4669), whereas the comparator group received PN prepared by a pharmacy (either hospital compounded or outsourced; n = 64,315). Observed data were adjusted using multivariate logistic regression for baseline differences, risk factors, and potential confounders, with propensity score matching as a sensitivity analysis. <italic>Results:</italic> The observed and adjusted BSI rates indicate that MCB is associated with fewer infections than pharmacy-prepared PN (observed 17.5% vs 26.6%; adjusted 19.6% vs 25.9%, both <italic>P</italic> &lt; .001). Propensity-matched scores found similar results with observed BSI rates of 18.9% in patients receiving MCB and 24.6% in patients receiving a compounded PN. <italic>Conclusion:</italic> Both the observed rate of BSI and adjusted probability of developing a BSI remained significantly lower for the MCB than the compounded PN group.</p>
</abstract>
<kwd-group>
<kwd>bloodstream</kwd>
<kwd>compounding</kwd>
<kwd>infection</kwd>
<kwd>multichamber bag</kwd>
<kwd>parenteral nutrition</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607111414714">
<title>Clinical Relevancy Statement</title>
<p>Reducing the risk of bloodstream infection in parenteral nutrition (PN) patients has the potential to improve both clinical and economic outcomes. This study was able to retrospectively evaluate the correlation between bloodstream infections in PN patients and the method used to prepare the PN mixture. The use of a large data source helps to minimize false results and provides insight for future prospective research.</p>
</sec>
<sec id="section2-0148607111414714" sec-type="intro">
<title>Introduction</title>
<p>Malnutrition occurs in patients who fail to receive adequate nutrition during critical illness.<sup><xref ref-type="bibr" rid="bibr1-0148607111414714">1</xref></sup> Although advancing an oral or enteral diet is optimal to maintain gastrointestinal tract function, intolerance to therapy increases the risk for a poor immune response, infection, catabolism, and longer hospital stay.<sup><xref ref-type="bibr" rid="bibr2-0148607111414714">2</xref>,<xref ref-type="bibr" rid="bibr3-0148607111414714">3</xref></sup> In addition, absorption of enteral nutrition (EN) in patients with inflammatory bowel diseases, intestinal failure, and malabsorption may be inadequate.<sup><xref ref-type="bibr" rid="bibr4-0148607111414714">4</xref>,<xref ref-type="bibr" rid="bibr5-0148607111414714">5</xref></sup> Supplementing the diet with parenteral nutrition (PN) ensures that a minimum of critical nutrients are provided to decrease the risks associated with malnutrition.<sup><xref ref-type="bibr" rid="bibr6-0148607111414714">6</xref></sup> However, the greater rates of infection, including bloodstream infection (BSI), that occur when using PN compared to EN<sup><xref ref-type="bibr" rid="bibr7-0148607111414714">7</xref></sup> have led many prescribers to minimize its use whenever possible. Joint guidelines issued in 2009 by the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) and the Society of Critical Care Medicine (SCCM) suggest restricting PN usage for the first 7 days following admission to the intensive care unit (ICU) in previously healthy and well-nourished patients who cannot be fed by the enteral route.<sup><xref ref-type="bibr" rid="bibr8-0148607111414714">8</xref></sup></p>
<p>BSI is a common cause of morbidity and mortality in the United States, with mortality rates reported at 12%−25%.<sup><xref ref-type="bibr" rid="bibr9-0148607111414714">9</xref></sup> Klevens et al<sup><xref ref-type="bibr" rid="bibr10-0148607111414714">10</xref></sup> estimated that approximately one-third of hospital healthcare-acquired infection (HAI) deaths were due to BSI.<sup><xref ref-type="bibr" rid="bibr10-0148607111414714">10</xref></sup> BSIs add substantial financial burden to hospitals because of longer hospital stays, medication use, and medical procedures. A case control study at a 2000-bed hospital in Rome found that each BSI case cost €16,356 (equivalent to $20,440).<sup><xref ref-type="bibr" rid="bibr11-0148607111414714">11</xref></sup> Kilgore and Brossette<sup><xref ref-type="bibr" rid="bibr12-0148607111414714">12</xref></sup> also found that each case of BSI was associated with an additional cost of $10,000–$20,000.</p>
<p>BSI rates among PN patients have been reported to vary widely from 1.3%−39%.<sup><xref ref-type="bibr" rid="bibr13-0148607111414714">13</xref>,<xref ref-type="bibr" rid="bibr14-0148607111414714">14</xref></sup> A recent cohort study among patients with central venous catheters, with or without PN, found that PN was an independent risk factor for BSI.<sup><xref ref-type="bibr" rid="bibr15-0148607111414714">15</xref></sup> Another cohort study in 19 Canadian hospitals found that the BSI rates among PN patients were 4 times higher than those not receiving PN.<sup><xref ref-type="bibr" rid="bibr16-0148607111414714">16</xref></sup></p>
<p>In the United States, PN is delivered as either standardized or individualized formulations that are compounded in a healthcare facility or outsourced to a compounding pharmacy.<sup><xref ref-type="bibr" rid="bibr17-0148607111414714">17</xref></sup> Standardized PN formulations are also commercially available in multichamber bags (MCBs). Both the European Society for Clinical Nutrition and Metabolism and A.S.P.E.N. recommend using standardized PN products when possible,<sup><xref ref-type="bibr" rid="bibr17-0148607111414714">17</xref>,<xref ref-type="bibr" rid="bibr18-0148607111414714">18</xref></sup> and it has been estimated that 60%−86% of patients receiving PN can have their nutrition needs met using a standardized formulation.<sup><xref ref-type="bibr" rid="bibr19-0148607111414714">19</xref>-<xref ref-type="bibr" rid="bibr21-0148607111414714">21</xref></sup></p>
<p>PN compounding involves the transfer of multiple sterile ingredients (dextrose, amino acids, electrolyte, vitamins, and minerals) into a single container using aseptic techniques.<sup><xref ref-type="bibr" rid="bibr22-0148607111414714">22</xref></sup> Each step in the process presents an opportunity for microbial contamination, and only when compounding involves ≤3 transfers is the risk considered low level.<sup><xref ref-type="bibr" rid="bibr23-0148607111414714">23</xref></sup> Pharmacists must comply with established sterile compounding standards,<sup><xref ref-type="bibr" rid="bibr23-0148607111414714">23</xref></sup> including cleanroom compounding, gowning, gloving, and validation of aseptic technique,<sup><xref ref-type="bibr" rid="bibr24-0148607111414714">24</xref></sup> to ensure that the preparation remains sterile. Poor aseptic technique and inadequate compounding practices may lead to contamination of the infusate, increasing the risk of infection in the patient. In an infant surgical unit, Scott et al<sup><xref ref-type="bibr" rid="bibr25-0148607111414714">25</xref></sup> observed contamination with coagulase-negative staphylococci and diphtheroids in 8.1% of the PN fluids and sets examined from 8 patients. A simulation of compounding suggested that PN contamination rates range from 4.4%−5.2%.<sup><xref ref-type="bibr" rid="bibr26-0148607111414714">26</xref></sup> In contrast, a 2-step compounding process is associated with &lt;0.1% contamination.<sup><xref ref-type="bibr" rid="bibr27-0148607111414714">27</xref></sup> Once contaminated, the potential for microbial growth in PN medium has been well documented in the literature.<sup><xref ref-type="bibr" rid="bibr28-0148607111414714">28</xref>,<xref ref-type="bibr" rid="bibr29-0148607111414714">29</xref></sup> A cohort study investigating the pathogenesis of catheter-related BSIs in neonates with a peripherally inserted central venous catheter found that 67% were derived from intraluminal contamination, which does not preclude the infusate as a contributing factor.<sup><xref ref-type="bibr" rid="bibr30-0148607111414714">30</xref></sup> In fact, contaminated PN has been attributed to sepsis when poor aseptic technique is used and enough patients are infected to warrant an investigation.<sup><xref ref-type="bibr" rid="bibr31-0148607111414714">31</xref>,<xref ref-type="bibr" rid="bibr32-0148607111414714">32</xref></sup> The association of BSI with different preparation methods of PN (commercial MCB vs pharmacy-compounded PN) has not been previously reported. The purpose of this study was to observe BSI rates in a large PN inpatient population to determine if PN prepared by different methods was associated with infection.</p>
</sec>
<sec id="section3-0148607111414714" sec-type="methods">
<title>Methods</title>
<sec id="section4-0148607111414714">
<title>Data Source</title>
<p>Inpatient data from a nationally representative hospital network database managed by Premier Healthcare Alliance were analyzed. The Premier Perspective comparative hospital database (PCD) covers &gt;400 hospitals and contains a total of 2.5 billion patient daily service records, with about 45 million records added each month. The database contains basic patient characteristics; <italic>International Classification of Diseases, 9th Revision</italic> (<italic>ICD-9</italic>) and <italic>Current Procedural Terminology</italic> (<italic>CPT</italic>) codes; and a date-stamped log of all billed items at the individual patient level. For this current study, data were available from 2005–2007, covering more than 11 million inpatient admissions.</p>
</sec>
<sec id="section5-0148607111414714">
<title>Study Population</title>
<p>Data analysis included all hospitalized patients 18 years and older who received PN from January 1, 2005, to December 31, 2007. Because bacterial infection, hepatic dysfunction, hypoglycemia, acute cholecystitis, phlebitis, thrombophlebitis, and pulmonary embolism were identified as either primary or secondary outcomes, patients admitted with those diagnoses were excluded from the analysis.</p>
<p>Administration of a PN solution was inferred if a patient had a claim for compounded PN solution or premixed MCB PN. Charge codes were identified from the Premier charge master file and searched for in the standard charge code description, clinical detail description, clinical summary description, and product name fields. All codes yielded by the search terms were reviewed by examining the product descriptions. The exposure cohort was defined as any patient who received PN via a standardized MCB (n = 4669). Our comparator group (PN prepared by compounding [CPN]) was defined as patients receiving PN prepared either in-hospital or outsourced to a centralized compounding center (n = 64,315). A subset of the CPN group who received PN compounded in the hospital pharmacy (HCPN) was included in the analyses (n = 978). Data from this subset were included in the overall CPN group as well as the separate analyses to provide insight into potential differences based on compounding location. The database did not always differentiate PN compounding sites, which resulted in a relatively small number of patients in the HCPN subgroup that we could be certain received hospital-compounded PN. Although it is possible that some hospitals administered both CPN and MCB, no single patient received both types of PN during an admission. Detailed description of the patient selection methodology is found in Mercaldi et al.<sup><xref ref-type="bibr" rid="bibr33-0148607111414714">33</xref></sup></p>
</sec>
</sec>
<sec id="section6-0148607111414714">
<title>Analysis</title>
<sec id="section7-0148607111414714">
<title>Outcome and Controlling Variables</title>
<p>We examined BSI rates as our primary dependent variable. BSI was defined as the occurrence of <italic>ICD-9</italic> codes of 038.x (septicemia), 995.91 (sepsis), 995.92 (severe sepsis), or 790.7 (bacteremia). A sensitivity analysis was conducted to determine the acceptability of these <italic>ICD-9</italic> codes to define BSI. <italic>ICD-9</italic> codes for hypoglycemia (251.2), hyperglycemia (249, 790.29), acute cholecystitis (575.0), and phlebitis, thrombophlebitis, or pulmonary embolism (451.82, 451.83, 451.84, 415.x) were secondary outcomes of interest. All data were analyzed using Statistical Analysis Software (SAS version 9.1; SAS Institute, Cary, NC).</p>
<p>Baseline characteristics of the cohort included hospital, patient, and PN treatment variables. Hospital variables examined were bed size, teaching status, geographic region, and metropolitan location. Patient characteristics included age, gender, ethnicity, comorbidities (ie, malnutrition, intestinal malabsorption, acute pancreatitis, peritonitis, gastrointestinal fistula, Crohn’s disease, cancer, cirrhosis or chronic liver disease, renal failure, diabetes mellitus, and tuberculosis), All Patient Refined Diagnosis Related Group (APR-DRG) severity class, and surgical, admission, and discharge status. PN treatment included days of PN, prior admission of PN, and daily PN volume. Independent <italic>t</italic> tests were used to compare continuous variables of the MCB and CPN groups. Two-group <italic>z</italic> tests compared observed BSI and mortality rates for the MCB and CPN groups. Analyses were repeated to compare the MCB and HCPN groups.</p>
<p>Multivariate logistic regression was used to create a model to calculate adjusted rates of BSIs per group and estimate the risk of BSI and mortality.<sup><xref ref-type="bibr" rid="bibr34-0148607111414714">34</xref></sup> This model included 29 variables that adjusted for baseline differences, risk factors, and potential confounders in the database, as listed above.</p>
<p>Variable-selection procedures were aimed at identifying a reduced set of independent variables to provide a best fit of the model. The final model was determined using backward elimination variable selection, with a significance level of .10 for the Wald χ<sup>2</sup> statistic to specify the covariates that would remain in each step. Model fit was assessed using the C-statistic, which corresponded to the area under a receiver operating characteristic (ROC) curve, and indicating the probability that randomly selected patients with the event have a higher predicted probability of the event than patients without the event. Risk of infection was reported as adjusted probability of the event and an odds ratio (OR) with 95% confidence interval (CI). We repeated these analyses to compare differences between the MCB and HCPN groups. A <italic>P</italic> value &lt;.05 was considered statistically significant.</p>
</sec>
<sec id="section8-0148607111414714">
<title>Risk and Time</title>
<p>Linear regression of BSI rates by number of days on PN was performed to understand the relationship between these 2 variables. Daily BSI rates (observed) for our total PN population were plotted against PN days.</p>
</sec>
<sec id="section9-0148607111414714">
<title>Sensitivity Analyses</title>
<p>In the first of 2 sensitivity analyses, we repeated our logistic regression using both <italic>ICD-9</italic> codes and the administration of any intravenous (IV) antibiotic following the initiation of PN to identify BSIs. This served as an accuracy check of the <italic>ICD-9</italic> codes used to identify BSIs.</p>
<p>Second, we used propensity score modeling to create balanced groups of patients receiving MCB and CPN.<sup><xref ref-type="bibr" rid="bibr35-0148607111414714">35</xref></sup> All 29 variables used in the initial model were included in the propensity modeling procedure. From this model, we obtained a propensity score for each subject reflecting the probability of a given type of PN, and each patient receiving MCB was matched 1:1 to a patient receiving CPN by a propensity score within a caliper of 0.05 (5%). MCB patients who could not be matched with this degree of accuracy were excluded from this analysis, resulting in a population of 3048 PN patients (n = 1524 MCB, n = 1524 CPN). The multivariate logistic regression models were then repeated on the matched groups.</p>
</sec>
</sec>
<sec id="section10-0148607111414714" sec-type="results">
<title>Results</title>
<sec id="section11-0148607111414714">
<title>Baseline and Treatment Characteristics</title>
<p>Of more than 11 million admissions recorded in the Premier database between 2005 and 2007, 112,845 patients received PN. Because we were interested in observing differences in several primary and secondary outcomes, including bacterial infection, hypo- and hyperglycemia, hepatic dysfunction, acute cholecystitis, phlebitis and thromophlebitis, we excluded 6471 patients who were admitted with these diagnoses. In addition, 34,307 neonates and 3083 pediatric patients were excluded, resulting in a final data set of 68,984 inpatients 18 years or older. Of these, 4669 patients received MCB, and 64,315 received CPN (either in-hospital compounded or outsourced). The HCPN subgroup analysis comprised 978 patients who received PN compounded on-site in the hospital pharmacy.</p>
<p>Patients who received MCB were slightly older and were less likely to have major or extreme APR-DRG severity or to expire in-hospital (<xref ref-type="table" rid="table1-0148607111414714">Table 1a</xref>). With regards to secondary outcomes, each represented a small proportion of both the MCB and the CPN groups (hypoglycemia, 0.2% vs 0.3%; hyperglycemia, 1.5% vs 1.7%; acute cholecystitis, 0.6% vs 0.6%; and phlebitis, thrombophlebitis, or pulmonary embolism, 2.4% vs 2.9%). Only hepatic dysfunction was significantly different between the 2 groups (1.5% vs 3.0%; <italic>P</italic> &lt; .001). The CPN group had more days on PN and slightly less daily PN volume (<xref ref-type="table" rid="table1-0148607111414714">Table 1b</xref>). Patients receiving HCPN had more days on PN but less volume per day compared to the other groups (<xref ref-type="table" rid="table1-0148607111414714">Table 1b</xref>).</p>
<table-wrap id="table1-0148607111414714" position="float">
<label>Table 1.</label>
<caption>
<p>All Patients: Patient and Treatment Characteristics at Baseline</p>
</caption>
<graphic alt-version="no" alternate-form-of="table1-0148607111414714" position="float" xlink:href="10.1177_0148607111414714-table1.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1"/>
<th align="center" colspan="1" rowspan="1">Multichamber Bags (n = 4669)</th>
<th align="center" colspan="1" rowspan="1">All Compounded (n = 64,315)</th>
<th align="center" colspan="1" rowspan="1">Hospital Compounded (n = 978)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4" rowspan="1">(a) Patient characteristics</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Age, mean (SD), y</td>
<td colspan="1" rowspan="1">67.4 (17)</td>
<td colspan="1" rowspan="1">64.2 (17)<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">60.7 (16.2)<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Gender, % male</td>
<td colspan="1" rowspan="1">43.2</td>
<td colspan="1" rowspan="1">47.1<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">57.5<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Major or extreme APR-DRG severity, %</td>
<td colspan="1" rowspan="1">72.5</td>
<td colspan="1" rowspan="1">81.3<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">86.8<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Urgent or emergency admission, %</td>
<td colspan="1" rowspan="1">86.0</td>
<td colspan="1" rowspan="1">76.8<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">81.1<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Payer, % public (Medicare)</td>
<td colspan="1" rowspan="1">67.7</td>
<td colspan="1" rowspan="1">57.9<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">52.9<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Inpatient mortality, %</td>
<td colspan="1" rowspan="1">15.2</td>
<td colspan="1" rowspan="1">18.0</td>
<td colspan="1" rowspan="1">23.2<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ICU stay, % yes</td>
<td colspan="1" rowspan="1">40.3</td>
<td colspan="1" rowspan="1">54.9<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">68.1<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="4" rowspan="1"> Comorbidities, %</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Malnutrition</td>
<td colspan="1" rowspan="1">31.1</td>
<td colspan="1" rowspan="1">33.4<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">30.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Surgery</td>
<td colspan="1" rowspan="1">73.5</td>
<td colspan="1" rowspan="1">86.6<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">85.5<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Cancer</td>
<td colspan="1" rowspan="1">36.9</td>
<td colspan="1" rowspan="1">39.1<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">44.4<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Peritonitis</td>
<td colspan="1" rowspan="1">6.1</td>
<td colspan="1" rowspan="1">9.2<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">11.1<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Renal failure</td>
<td colspan="1" rowspan="1">25.4</td>
<td colspan="1" rowspan="1">31.7<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">36.1<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Diabetes mellitus</td>
<td colspan="1" rowspan="1">27.8</td>
<td colspan="1" rowspan="1">24.2<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">20.9<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Crohn’s disease</td>
<td colspan="1" rowspan="1">1.3</td>
<td colspan="1" rowspan="1">2.6<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">1.3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Total hospital days, mean (SD; median)</td>
<td colspan="1" rowspan="1">15 (13.7; 12)</td>
<td colspan="1" rowspan="1">19.1 (17.4; 15)<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">24 (23; 18)<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="4" rowspan="1">(b) Treatment characteristics</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Days on PN, mean (SD)</td>
<td colspan="1" rowspan="1">5.5 (5.0)</td>
<td colspan="1" rowspan="1">8.4 (9.1)<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
<td colspan="1" rowspan="1">9.3 (10.6)<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PN volume/d, mean (SD), mL</td>
<td colspan="1" rowspan="1">2109 (953)</td>
<td colspan="1" rowspan="1">2087 (1398)</td>
<td colspan="1" rowspan="1">1162 (405)<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414714">a</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607111414714">
<p>APR-DRG, All Patient Refined Diagnosis Related Group; ICU, intensive care unit; PN, parenteral nutrition.</p>
</fn>
<fn id="table-fn2-0148607111414714">
<label>a</label>
<p><italic>P</italic> &lt; .01 compared to multichamber bags.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-0148607111414714">
<title>BSI Rates</title>
<p><xref ref-type="fig" rid="fig1-0148607111414714">Figure 1</xref> depicts the observed and adjusted BSI rates between the MCB and CPN groups. The observed BSI rate in the MCB group was 17.5%, significantly lower than that of the CPN group (26.6%; <italic>P</italic> &lt; .001). Our model used the 29 hospital, patient, and PN variables previously described to control for identifiable risk factors and calculated BSI rates that adjusted for any observed differences in risk between the groups. After adjustment, the BSI rate was still significantly different (19.6% vs 25.9%, <italic>P</italic> &lt; .001; OR = 1.54; 95% CI, 1.39–1.69).</p>
<fig id="fig1-0148607111414714" position="float">
<label>Figure 1.</label>
<caption>
<p>Comparison of bloodstream infection (BSI) rates for MCB (multichamber bag) and CPN (compounded parenteral nutrition) groups. Odds ratio for adjusted BSI rate = 1.54; 95% confidence interval, 1.39–1.69.</p>
</caption>
<graphic alt-version="no" position="float" xlink:href="10.1177_0148607111414714-fig1.tif" xlink:type="simple"/>
</fig>
<p><xref ref-type="fig" rid="fig2-0148607111414714">Figure 2</xref> depicts the observed and adjusted BSI rates between the MCB and HCPN groups. Similarly, the observed BSI rate in the MCB group (17.5%) was significantly lower than that of the HCPN group (38.0%; <italic>P</italic> &lt; .001). After adjustment, this difference narrowed but was still significantly different (17.5% vs 30.9%, <italic>P</italic> &lt; .001; OR = 2.50; 95% CI, 1.96–3.12).</p>
<fig id="fig2-0148607111414714" position="float">
<label>Figure 2.</label>
<caption>
<p>Comparison of bloodstream infection (BSI) rates for MCB (multichamber bag) and HCPN (parenteral nutrition compounded in a hospital pharmacy) groups. Odds ratio for adjusted BSI rate = 2.50; 95% confidence interval, 1.96–3.12.</p>
</caption>
<graphic alt-version="no" position="float" xlink:href="10.1177_0148607111414714-fig2.tif" xlink:type="simple"/>
</fig>
</sec>
<sec id="section13-0148607111414714">
<title>Risk and Time</title>
<p><xref ref-type="fig" rid="fig3-0148607111414714">Figure 3</xref> depicts the relationship between BSI risk and days on PN. The mean number of PN days in our total population was 8.2 days, with a standard deviation of 8.9 and a median of 6 days, and thus most patients were clustered in the lower left corner. The strong linear relationship (<italic>P</italic> &lt; .0001) between risk and time exists over the first 50 days of PN therapy. Beyond that time, the relationship strays from the expected but remains higher than the 15-day risk.</p>
<fig id="fig3-0148607111414714" position="float">
<label>Figure 3.</label>
<caption>
<p>Rate of bloodstream infections (BSI) by days of parenteral nutrition (PN).</p>
</caption>
<graphic alt-version="no" position="float" xlink:href="10.1177_0148607111414714-fig3.tif" xlink:type="simple"/>
</fig>
</sec>
<sec id="section14-0148607111414714">
<title>Sensitivity Analysis</title>
<p>The first sensitivity analysis repeated the logistic regression for patients with a BSI, identified through both <italic>ICD-9</italic> codes and the administration of any IV antibiotic following their first PN day. Because there were only 73 patients in the HCPN group after matching, their characteristics are not displayed. After matching, several significant differences remained between the propensity score–matched groups (<xref ref-type="table" rid="table2-0148607111414714">Table 2</xref>). These patients represented 39 hospitals using MCB and 142 hospitals using CPN. There were no significant differences between the groups in terms of gender, most comorbidities, mortality, and days of PN therapy.</p>
<table-wrap id="table2-0148607111414714" position="float">
<label>Table 2.</label>
<caption>
<p>Propensity Score Matched Data: Patient and Treatment Characteristics at Baseline</p>
</caption>
<graphic alt-version="no" alternate-form-of="table2-0148607111414714" position="float" xlink:href="10.1177_0148607111414714-table2.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1"/>
<th align="left" colspan="1" rowspan="1">Multichamber Bags (n = 1524)</th>
<th align="center" colspan="1" rowspan="1">All Compounded (n = 1524)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3" rowspan="1">(a) Patient characteristics</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Age, mean (SD), y</td>
<td colspan="1" rowspan="1">66.5 (17.1)</td>
<td colspan="1" rowspan="1">64.9 (16.9)<sup><xref ref-type="table-fn" rid="table-fn4-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Gender, % male</td>
<td colspan="1" rowspan="1">46.2</td>
<td colspan="1" rowspan="1">48.8</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Major or extreme APR-DRG severity, %</td>
<td colspan="1" rowspan="1">76.3</td>
<td colspan="1" rowspan="1">80.2</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Urgent or emergency admission, %</td>
<td colspan="1" rowspan="1">77.7</td>
<td colspan="1" rowspan="1">80.6</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Payer, % public (Medicare)</td>
<td colspan="1" rowspan="1">64.0</td>
<td colspan="1" rowspan="1">59.9</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Inpatient mortality, %</td>
<td colspan="1" rowspan="1">14.6</td>
<td colspan="1" rowspan="1">17.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ICU stay, % yes</td>
<td colspan="1" rowspan="1">43.6</td>
<td colspan="1" rowspan="1">52.1<sup><xref ref-type="table-fn" rid="table-fn4-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="3" rowspan="1"> Comorbidities, %</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Malnutrition</td>
<td colspan="1" rowspan="1">32.6</td>
<td colspan="1" rowspan="1">32.7</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Surgery</td>
<td colspan="1" rowspan="1">80.8</td>
<td colspan="1" rowspan="1">82.3</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Cancer</td>
<td colspan="1" rowspan="1">37.3</td>
<td colspan="1" rowspan="1">36.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Peritonitis</td>
<td colspan="1" rowspan="1">7.2</td>
<td colspan="1" rowspan="1">7.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Renal failure</td>
<td colspan="1" rowspan="1">27.6</td>
<td colspan="1" rowspan="1">26.9</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Diabetes mellitus</td>
<td colspan="1" rowspan="1">29.1</td>
<td colspan="1" rowspan="1">22.0<sup><xref ref-type="table-fn" rid="table-fn4-0148607111414714">a</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Crohn’s disease</td>
<td colspan="1" rowspan="1">1.3</td>
<td colspan="1" rowspan="1">1.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Total hospital days, mean (SD; median)</td>
<td colspan="1" rowspan="1">17.5 (17.5; 13)</td>
<td colspan="1" rowspan="1">17 (15.2; 14)</td>
</tr>
<tr>
<td colspan="3" rowspan="1">(b) Treatment characteristics</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Days on PN, mean (SD)</td>
<td colspan="1" rowspan="1">6.1 (6.0)</td>
<td colspan="1" rowspan="1">6.5 (5.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PN volume per day, mean (SD), mL</td>
<td colspan="1" rowspan="1">1905 (929)</td>
<td colspan="1" rowspan="1">2267 (1817)<sup><xref ref-type="table-fn" rid="table-fn4-0148607111414714">a</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0148607111414714">
<p>APR-DRG, All Patient Refined Diagnosis Related Group; ICU, intensive care unit; PN, parenteral nutrition.</p>
</fn>
<fn id="table-fn4-0148607111414714">
<label>a</label>
<p><italic>P</italic> &lt; .01.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="fig" rid="fig4-0148607111414714">Figure 4</xref> depicts differences between the observed and adjusted BSI rates using the propensity score–matched MCB and CPN groups. Both the observed and adjusted BSI rates were significantly different between the MCB and CPN groups.</p>
<fig id="fig4-0148607111414714" position="float">
<label>Figure 4.</label>
<caption>
<p>Bloodstream infection (BSI) rates for propensity score matched for MCB (multichamber bag) and CPN (compounded parenteral nutrition) groups. Odds ratio for adjusted BSI rate = 1.49; 95% confidence interval, 1.23–1.82.</p>
</caption>
<graphic alt-version="no" position="float" xlink:href="10.1177_0148607111414714-fig4.tif" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="section15-0148607111414714" sec-type="discussion">
<title>Discussion</title>
<p>Our analyses indicate that patients who received MCB were treated in smaller, nonteaching hospitals. Patients receiving MCB also tended to be older, female, and on public funding, with less apparent disease acuity. This lower severity may, in part, explain the lower inpatient mortality rate among MCB patients, as well as the shorter duration of hospitalization, fewer PN days, and lower rates of BSI. However, the severity was no different between observed and adjusted BSI rates in the propensity score–matched groups, suggesting that something other than severity contributed to the findings.</p>
<p>Treating a BSI is very costly and prolongs hospitalization.<sup><xref ref-type="bibr" rid="bibr12-0148607111414714">12</xref></sup> The observed BSI rates indicate that MCB is associated with fewer infections compared to CPN, particularly in the HCPN subgroup. After adjustment, the difference between the MCB and CPN groups narrowed but was still significantly different. In the sensitivity analysis, propensity score models demonstrated findings similar to the original logistic regression for BSI rates in the MCB and CPN groups. In both analyses, the risk of developing a BSI when using MCB was significantly lower when compared to CPN.</p>
<p>Our findings raise important questions for patient safety, pharmacy compounding practices, and future research. Avoiding a BSI is an important patient safety issue that could potentially reduce mortality rates. Because of the significant toll they exact on human lives, the U.S. Department of Health and Human Services, in its Action Plan to Prevent Healthcare-Associated Infections, has targeted a 50% reduction in central line–associated bloodstream infections and a 100% compliance rate with insertion safety procedures (nonemergent insertions) over the next 5 years.<sup><xref ref-type="bibr" rid="bibr36-0148607111414714">36</xref></sup> One of the only simulated PN preparation studies showed that approximately 1 out of every 20 formulations were contaminated by the compounding pharmacy staff.<sup><xref ref-type="bibr" rid="bibr26-0148607111414714">26</xref></sup> These findings might explain the difference in BSI rates based on PN preparation methods.</p>
<p>The majority of serious BSIs are associated with central venous catheters.<sup><xref ref-type="bibr" rid="bibr37-0148607111414714">37</xref></sup> Our study demonstrated an increased risk of BSIs as the number of days on PN increases. In general, the risk of BSI is greater if the patient has a central vs peripheral catheter,<sup><xref ref-type="bibr" rid="bibr38-0148607111414714">38</xref></sup> has a central venous catheter placed for &gt;30 days, or has an ICU stay.<sup><xref ref-type="bibr" rid="bibr34-0148607111414714">34</xref></sup> The European Sepsis Group reported that 28% of BSIs in ICU patients with a central catheter were associated with sepsis, 24% with severe sepsis, and 30% with septic shock.<sup><xref ref-type="bibr" rid="bibr39-0148607111414714">39</xref></sup></p>
<p>The Keystone ICU project demonstrated that following an evidence-based protocol, as recommended by the Centers for Disease Control and Prevention (CDC), can have a significant impact on bloodstream infections.<sup><xref ref-type="bibr" rid="bibr40-0148607111414714">40</xref></sup> These recommendations included hand washing, using full-barrier precautions, cleaning the skin with chlorhexidine, avoiding the femoral site if possible, and removing unnecessary catheters. Across the 108 ICUs in the study, the mean BSI rates were reduced from a baseline of 7.7 infections per 1000 catheter days to 1.4 infections per 1000 catheter days during 18 months of follow-up.<sup><xref ref-type="bibr" rid="bibr40-0148607111414714">40</xref></sup> Sterile equipment, hand hygiene, aseptic technique, routine dressing changes, in-line filters, and skin disinfection are all recommended to minimize infection.<sup><xref ref-type="bibr" rid="bibr35-0148607111414714">35</xref>,<xref ref-type="bibr" rid="bibr41-0148607111414714">41</xref></sup> Although not specifically linked to PN delivery systems, closed systems in general have been associated with BSI reduction of at least 50% when compared to the use of an open system<sup><xref ref-type="bibr" rid="bibr42-0148607111414714">42</xref>-<xref ref-type="bibr" rid="bibr46-0148607111414714">46</xref></sup> and have demonstrated cost effectiveness.<sup><xref ref-type="bibr" rid="bibr47-0148607111414714">47</xref></sup></p>
<p>Although our analysis reflects the real-world use of PN, it does have several important limitations. First, the lack of randomization limits our capacity to determine a causal relationship between PN type and BSI rates. Second, because we could not reliably identify the presence or type of IV catheters, we were unable to report BSI/catheter days as recommended by some organizations, including the CDC and the Joint Commission. The medical literature has reported BSI rates with PN in the range of 7.2%−39% that provides an appropriate context for our findings.<sup><xref ref-type="bibr" rid="bibr13-0148607111414714">13</xref>,<xref ref-type="bibr" rid="bibr16-0148607111414714">16</xref></sup> Although central catheters are an infection risk, we were able to include many of the variables in our analysis that are correlated with central line use (eg, diagnosis, comorbidities, surgical status, number of hospital PN days).</p>
<p>In addition, although our sensitivity analysis confirmed that <italic>ICD-9</italic> codes were likely adequate in identifying infection, this was not validated through individual patient records. BSIs due to IV access sites and its manipulations cannot be distinguished from sepsis due to other causes. To identify a specific infection would require formal chart reviews for microbiology profiles of a positive culture report. However, it is likely that any error in identifying infections was random across both the MCB and CPN groups. It is also important to note that although the total CPN group consisted of 161 hospitals that exclusively used compounded PN, we were only able to reliably identify 8 hospitals that compounded on-site for our HCPN subgroup analysis. The remaining 153 CPN hospitals either outsourced or compounded on-site.</p>
<p>Our models adjusted for numerous variables that affected BSI rates, but we cannot guarantee that all sources of variance have been recognized because only variables measured in the database were included. Nonetheless, the large population in our analysis provides us the opportunity to raise these issues and guide further study into this relationship.</p>
<p>Despite the limitations imposed by retrospective database analyses, these types of studies are used by the Food and Drug Administration to detect and explore safety signals for marketed drugs.<sup><xref ref-type="bibr" rid="bibr48-0148607111414714">48</xref></sup> One of the best-known examples was the identification of increased coronary symptoms associated with cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs in the early 2000s. Epidemiologic studies of large retrospective databases led to further study and eventually the withdrawal of valdecoxib (Bextra) and refocoxib (Vioxx) from the U.S. market.<sup><xref ref-type="bibr" rid="bibr48-0148607111414714">48</xref>,<xref ref-type="bibr" rid="bibr49-0148607111414714">49</xref></sup></p>
<p>Our analysis is one of the first reports describing PN patients and associated BSI rates in the real-world setting. The CPN group had a higher patient acuity, higher observed BSI rate, and longer length of stay than those who received MCB. Once illness severity and other baseline variables were accounted for, the adjusted probability of BSIs remained significantly lower for the MCB than the CPN group, particularly when compared to the HCPN group. These results were replicated in the sensitivity analyses. These findings are useful for generating hypotheses for a large-scale study and may provide impetus for individual hospital-focused quality improvement for patient safety, pharmacy compounding practices, and infection control initiatives.</p>
</sec>
</body>
<back>
<ack><p>The authors thank Matthew Reynolds, PhD, for his insight into the data analyses and the other members of the IMPROVE Study Group for their discussions and guidance.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This study was funded by Baxter Healthcare.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607111414714">
<label>1.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Keith</surname><given-names>JN</given-names></name>
</person-group>. <article-title>Bedside nutrition assessment past, present and future: a review of the Subjective Global Assessment</article-title>. <source>Nutr Clin Pract</source>. <year>2008</year>;<volume>23</volume>:<fpage>410</fpage>-<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr2-0148607111414714">
<label>2.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Heyland</surname><given-names>DK</given-names></name>
<name name-style="western"><surname>McClave</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Nutrition in the critically ill</article-title>. In: <person-group person-group-type="editor">
<name name-style="western"><surname>Hall</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Schmidt</surname><given-names>GA</given-names></name>
<name name-style="western"><surname>Wood</surname><given-names>LDH</given-names></name>
</person-group>, eds. <source>Principles of Critical Care</source>. <edition>3rd ed</edition>. <publisher-loc>Columbus, OH</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>; <year>2005</year>.</citation>
</ref>
<ref id="bibr3-0148607111414714">
<label>3.</label>
<citation citation-type="web" xlink:type="simple"><collab xlink:type="simple">European Public Health Alliance</collab>. <comment>The cost of malnutrition in the UK</comment>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.epha.org/a/2080" xlink:type="simple">http://www.epha.org/a/2080</ext-link></comment>. <access-date>Accessed on May 28, 2010</access-date>.</citation>
</ref>
<ref id="bibr4-0148607111414714">
<label>4.</label>
<citation citation-type="journal" xlink:type="simple"><collab xlink:type="simple">A.S.P.E.N. Board of Directors</collab>. <article-title>Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2002</year>;<volume>26</volume>:<fpage>1SA</fpage>-<lpage>138SA</lpage>.</citation>
</ref>
<ref id="bibr5-0148607111414714">
<label>5.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="editor">
<name name-style="western"><surname>Rolfes</surname><given-names>SR</given-names></name>
<name name-style="western"><surname>Pinna</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Whitney</surname><given-names>E</given-names></name>
</person-group>, eds. <source>Understanding Normal and Clinical Nutrition</source>. <edition>7th ed</edition>. <publisher-loc>Belmont, CA</publisher-loc>: <publisher-name>Thomson Wadsworth</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr6-0148607111414714">
<label>6.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Forchielli</surname><given-names>ML</given-names></name>
<name name-style="western"><surname>Miller</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Nutritional goals and requirements</article-title>. In: <person-group person-group-type="editor">
<name name-style="western"><surname>Merritt</surname><given-names>R</given-names></name>
</person-group>, ed. <source>The A.S.P.E.N. Nutrition Support Practice Manual</source>. <edition>2nd ed</edition>. <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>American Society for Parenteral and Enteral Nutrition</publisher-name>; <year>2005</year>:<fpage>38</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr7-0148607111414714">
<label>7.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Braunschweig</surname><given-names>CL</given-names></name>
<name name-style="western"><surname>Levy</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Sheean</surname><given-names>PM</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>
</person-group>. <article-title>Enteral compared with parenteral nutrition: a meta-analysis</article-title>. <source>Am J Clin Nutr</source>. <year>2001</year>;<volume>74</volume>:<fpage>534</fpage>-<lpage>542</lpage>.</citation>
</ref>
<ref id="bibr8-0148607111414714">
<label>8.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>McClave</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Martindale</surname><given-names>RG</given-names></name>
<name name-style="western"><surname>Vanek</surname><given-names>VW</given-names></name>
<etal/>
</person-group>; <collab xlink:type="simple">A.S.P.E.N. Board of Directors; American College of Critical Care Medicine; Society of Critical Care Medicine</collab>. <article-title>Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>(<issue>3</issue>):<fpage>277</fpage>-<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr9-0148607111414714">
<label>9.</label>
<citation citation-type="journal" xlink:type="simple"><collab xlink:type="simple">Centers for Disease Control and Prevention (CDC)</collab>. <article-title>Reduction in central-line associated bloodstream infection among patients in intensive care units—Pennsylvania—April 2001–March 2005</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2005</year>;<volume>54</volume>:<fpage>1013</fpage>-<lpage>1016</lpage>.</citation>
</ref>
<ref id="bibr10-0148607111414714">
<label>10.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Klevens</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Edwards</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Richards</surname><given-names>CL</given-names></name>
<etal/>
</person-group>. <article-title>Estimating health care-associated infections and deaths in U.S. hospitals, 2002</article-title>. <source>Public Health Rep</source>. <year>2007</year>;<volume>122</volume>:<fpage>160</fpage>-<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr11-0148607111414714">
<label>11.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Orsi</surname><given-names>GB</given-names></name>
<name name-style="western"><surname>Di Stefano</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Noah</surname><given-names>N</given-names></name>
</person-group>. <article-title>Hospital-acquired, laboratory-confirmed bloodstream infection: increased hospital stay and direct cost</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2002</year>;<volume>23</volume>:<fpage>190</fpage>-<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr12-0148607111414714">
<label>12.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kilgore</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Brossette</surname><given-names>S</given-names></name>
</person-group>. <article-title>Cost of bloodstream infections</article-title>. <source>Am J Infect Control</source>. <year>2008</year>;<volume>36</volume>:<fpage>S172.e1</fpage>-<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr13-0148607111414714">
<label>13.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dissanaike</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Shelton</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Warner</surname><given-names>K</given-names></name>
<name name-style="western"><surname>O’Keefe</surname><given-names>GE</given-names></name>
</person-group>. <article-title>The risk of bloodstream infections is associated with increased parenteral caloric intake in patients receiving parenteral nutrition</article-title>. <source>Crit Care</source>. <year>2007</year>;<volume>11</volume>:<fpage>R114</fpage>.</citation>
</ref>
<ref id="bibr14-0148607111414714">
<label>14.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Opilla</surname><given-names>M</given-names></name>
</person-group>. <article-title>Epidemiology of bloodstream infection associated with parenteral nutrition</article-title>. <source>Am J Infect Control</source>. <year>2008</year>;<volume>36</volume>:<fpage>S173.e5</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr15-0148607111414714">
<label>15.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Beghetto</surname><given-names>MG</given-names></name>
<name name-style="western"><surname>Victorino</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Teixeira</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Azevedo</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Parenteral nutrition as a risk factor for central venous catheter-related infection</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2005</year>;<volume>29</volume>:<fpage>367</fpage>-<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr16-0148607111414714">
<label>16.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Holton</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Paton</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Conly</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Embree</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Taylor</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Thompson</surname><given-names>W</given-names></name>
</person-group>. <article-title>Central venous catheter–associated bloodstream infections occurring in Canadian intensive care units: a six-month cohort study</article-title>. <source>Can J Infect Dis Med Microbiol</source>. <year>2006</year>;<volume>17</volume>:<fpage>169</fpage>-<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr17-0148607111414714">
<label>17.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kochevar</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Guenter</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Holcombe</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Malone</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Mirtallo</surname><given-names>J</given-names></name>
</person-group>; <article-title>A.S.P.E.N. Board of Directors and Task Force on Parenteral Nutrition Standardization. A.S.P.E.N. statement on parenteral nutrition standardization</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2007</year>;<volume>31</volume>:<fpage>441</fpage>-<lpage>448</lpage>.</citation>
</ref>
<ref id="bibr18-0148607111414714">
<label>18.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Singer</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Berger</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Van den Berghe</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>ESPEN guidelines on parenteral nutrition: intensive care</article-title>. <source>Clin Nutr</source>. <year>2009</year>;<volume>28</volume>:<fpage>387</fpage>-<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr19-0148607111414714">
<label>19.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Ruano</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Recuenco</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Torrecilla</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Standard formulas of parenteral nutrition: a study of their use in a general hospital</article-title>. <source>Nutr Hosp</source>. <year>1993</year>;<volume>8</volume>:<fpage>242</fpage>-<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr20-0148607111414714">
<label>20.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Radzwell</surname><given-names>R</given-names></name>
</person-group>. <article-title>Compounding of IV admixtures for parenteral nutrition in German hospital pharmacist</article-title>. <source>Krankenhauspharmazie</source>. <year>1997</year>;<month>May</month>:<fpage>230</fpage>-<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr21-0148607111414714">
<label>21.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Maisonneuve</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Raguso</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Paoloni-Giacobino</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Parenteral nutrition practices in hospital pharmacies in Switzerland, France, and Belgium</article-title>. <source>Nutrition</source>. <year>2004</year>;<volume>20</volume>:<fpage>528</fpage>-<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr22-0148607111414714">
<label>22.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Sanborn</surname><given-names>M</given-names></name>
</person-group>. <article-title>Core competencies in hospital pharmacy—intravenous admixtures</article-title>. <source>Hosp Pharm</source>. <year>2006</year>;<volume>41</volume>:<fpage>377</fpage>-<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr23-0148607111414714">
<label>23.</label>
<citation citation-type="book" xlink:type="simple"><comment>Chapter &lt;797&gt;</comment>. In: <source>USP 31/NF 26</source>. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>The United States Pharmacopeial Convention</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr24-0148607111414714">
<label>24.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mirtallo</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Canada</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Safe practices for parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2004</year>;<volume>28</volume>:<fpage>S39</fpage>-<lpage>S70</lpage>.</citation>
</ref>
<ref id="bibr25-0148607111414714">
<label>25.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Scott</surname><given-names>EM</given-names></name>
<name name-style="western"><surname>Gorman</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>Wyatt</surname><given-names>TD</given-names></name>
<name name-style="western"><surname>Magill</surname><given-names>EA</given-names></name>
</person-group>. <article-title>Growth of microorganisms in total parenteral nutrition mixtures and related clinical observations</article-title>. <source>J Clin Hosp Pharm</source>. <year>1985</year>;<volume>10</volume>(<issue>1</issue>):<fpage>79</fpage>-<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr26-0148607111414714">
<label>26.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Trissel</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Gentempo</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Anderson</surname><given-names>RW</given-names></name>
<name name-style="western"><surname>Lajeunesse</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk-level compounding</article-title>. <source>Am J Health Syst Pharm</source>. <year>2005</year>;<volume>62</volume>:<fpage>285</fpage>-<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr27-0148607111414714">
<label>27.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Trissel</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Ogundele</surname><given-names>AB</given-names></name>
<name name-style="western"><surname>Ingram</surname><given-names>DS</given-names></name>
<name name-style="western"><surname>Saenz</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Gentempo</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compounding</article-title>. <source>Am J Health Syst Pharm</source>. <year>2003</year>;<volume>60</volume>(<issue>18</issue>):<fpage>1853</fpage>-<lpage>1855</lpage>.</citation>
</ref>
<ref id="bibr28-0148607111414714">
<label>28.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kuwahara</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Kaneda</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Shimono</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Inoue</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Growth of microorganisms in total parenteral nutrition solutions without lipid</article-title>. <source>Int J Med Sci</source>. <year>2010</year>;<volume>7</volume>(<issue>1</issue>):<fpage>43</fpage>-<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr29-0148607111414714">
<label>29.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kuwahara</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Shimono</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Kaneda</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Tamura</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Ichihara</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Nakashima</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Growth of microorganisms in total parenteral nutrition solutions containing lipid</article-title>. <source>Int J Med Sci</source>. <year>2010</year>;<volume>7</volume>(<issue>3</issue>):<fpage>101</fpage>-<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr30-0148607111414714">
<label>30.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Garland</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Alex</surname><given-names>CP</given-names></name>
<name name-style="western"><surname>Sevallius</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Cohort study of the pathogenesis and molecular epidemiology of catheter-related bloodstream infection in neonates with peripherally inserted central venous catheters</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2008</year>;<volume>29</volume>(<issue>3</issue>):<fpage>243</fpage>-<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr31-0148607111414714">
<label>31.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Arslan</surname><given-names>U</given-names></name>
<name name-style="western"><surname>Erayman</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Kirdar</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Serratia marcescens sepsis outbreak in a neonatal intensive care unit</article-title>. <source>Pediatr Int</source>. <year>2010</year>;<volume>52</volume>(<issue>2</issue>):<fpage>208</fpage>-<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr32-0148607111414714">
<label>32.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>DiazGranados</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Martinez</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Deaza</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Valderrama</surname><given-names>S</given-names></name>
</person-group>. <article-title>An outbreak of Candida spp. bloodstream infection in a tertiary care center in Bogotá, Colombia</article-title>. <source>Braz J Infect Dis</source>. <year>2008</year>;<volume>12</volume>(<issue>5</issue>):<fpage>390</fpage>-<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr33-0148607111414714">
<label>33.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mercaldi</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Reynolds</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Turpin</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Methods to identify and compare parenteral nutrition administered from hospital compounded and premixed multichamber bags in a retrospective hospital claims database</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year> <month>Jul</month> <day>12</day>. [<comment>Epub ahead of print</comment>]</citation>
</ref>
<ref id="bibr34-0148607111414714">
<label>34.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Yoshida</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Ishimaru</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Fujimoto</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hirata</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Matsubara</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Koyanagi</surname><given-names>N</given-names></name>
</person-group>. <article-title>Risk factors for central venous catheter–related bloodstream infection: a 1073-patient study</article-title>. <source>J Infect Chemother</source>. <year>2008</year>;<volume>14</volume>(<issue>6</issue>):<fpage>399</fpage>-<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr35-0148607111414714">
<label>35.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rubin</surname><given-names>DB</given-names></name>
</person-group>. <article-title>Estimating causal effects from large data sets using propensity scores</article-title>. <source>Ann Intern Med</source>. <year>1997</year>;<volume>127</volume>:<fpage>757</fpage>-<lpage>763</lpage>.</citation>
</ref>
<ref id="bibr36-0148607111414714">
<label>36.</label>
<citation citation-type="gov" xlink:type="simple"><collab xlink:type="simple">U.S. Department of Health &amp; Human Services</collab>. <source>HHS Action Plan to Prevent Healthcare-Associated Infections</source>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.hhs.gov/ophs/initiatives/hai/infection.html" xlink:type="simple">http://www.hhs.gov/ophs/initiatives/hai/infection.html</ext-link></comment>. <access-date>Accessed July 7, 2010</access-date>.</citation>
</ref>
<ref id="bibr37-0148607111414714">
<label>37.</label>
<citation citation-type="journal" xlink:type="simple">
<collab xlink:type="simple">Centers for Disease Control and Prevention</collab>. <article-title>Guidelines for the prevention of intravascular catheter-related infections</article-title>. <source>MMWR Recomm Rep</source>. <year>2002</year>;<volume>51</volume>:<fpage>1</fpage>-<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr38-0148607111414714">
<label>38.</label>
<citation citation-type="book" xlink:type="simple">
<collab xlink:type="simple">World Health Organization</collab>. <article-title>Prevention of nosocomial infection</article-title>. In: <person-group person-group-type="editor">
<name name-style="western"><surname>Ducel</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Fabry</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Nicolle</surname><given-names>L</given-names></name>
</person-group>, eds. <source>Prevention of Hospital-Acquired Infections: A Practical Guide</source>. <edition>2nd ed</edition>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2002</year>:<fpage>30</fpage>-<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr39-0148607111414714">
<label>39.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Donelli</surname><given-names>G</given-names></name>
</person-group>. <article-title>Vascular catheter-related infection and sepsis</article-title>. <source>Surg Infect (Larchmt)</source>. <year>2006</year>;<volume>7</volume>(<issue>suppl 2</issue>):<fpage>S25</fpage>-<lpage>S27</lpage>.</citation>
</ref>
<ref id="bibr40-0148607111414714">
<label>40.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Pronovost</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Needham</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Berenholtz</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>An intervention to decrease catheter-related bloodstream infections in the ICU</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>:<fpage>2725</fpage>-<lpage>2732</lpage>.</citation>
</ref>
<ref id="bibr41-0148607111414714">
<label>41.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Donolan</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Costerton</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Biofilms: survival mechanisms of clinically relevant microorganisms</article-title>. <source>Clin Microbiol Rev</source>. <year>2002</year>;<volume>15</volume>:<fpage>167</fpage>-<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr42-0148607111414714">
<label>42.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Franzetti</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Borghi</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Raimondi</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Rosenthal</surname><given-names>VD</given-names></name>
</person-group>. <article-title>Impact on rates and time to first central vascular–associated bloodstream infection when switching from open to closed intravenous infusion containers in a hospital setting</article-title>. <source>Epidemiol Infect</source>. <year>2009</year>;<volume>137</volume>:<fpage>1041</fpage>-<lpage>1048</lpage>.</citation>
</ref>
<ref id="bibr43-0148607111414714">
<label>43.</label>
<citation citation-type="confproc" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rangel-Frausto</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Higuera</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Rosenthal</surname><given-names>VD</given-names></name>
<etal/>
</person-group>. <article-title>Probability of developing a central vascular catheter–associated bloodstream infection when comparing open and closed infusion systems in Mexico</article-title>. <conf-name>Presented at: Society for Healthcare Epidemiology of America 17th Annual Scientific Meeting</conf-name>; <conf-date>April 14-17, 2007</conf-date>; <conf-loc>Baltimore, MD</conf-loc>.</citation>
</ref>
<ref id="bibr44-0148607111414714">
<label>44.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rosenthal</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Maki</surname><given-names>DG</given-names></name>
</person-group>. <article-title>Prospective study of the impact of open and closed infusion systems on rates of central venous catheter–associated bacteremia</article-title>. <source>Am J Infect Control</source>. <year>2004</year>;<volume>32</volume>:<fpage>135</fpage>-<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr45-0148607111414714">
<label>45.</label>
<citation citation-type="confproc" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Salomao</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Rosenthal</surname><given-names>VD</given-names></name>
<name name-style="western"><surname>Blecher</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Maretti da Silva</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Vilins</surname><given-names>M</given-names></name>
<name name-style="western"><surname>da Silva</surname><given-names>EH</given-names></name>
</person-group>. <article-title>Probability of developing a central vascular catheter associated bloodstream infection when comparing open and closed infusion systems in Brazil</article-title>. <conf-name>Presented at: 47th Annual Scientific Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy</conf-name>; <conf-date>September 18, 2007</conf-date>; <conf-loc>Chicago, IL</conf-loc>.</citation>
</ref>
<ref id="bibr46-0148607111414714">
<label>46.</label>
<citation citation-type="confproc" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Salomao</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Blecher</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Rosenthal</surname><given-names>VD</given-names></name>
<name name-style="western"><surname>Maretti da Silva</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Vilins</surname><given-names>M</given-names></name>
<name name-style="western"><surname>da Silva</surname><given-names>EH</given-names></name>
</person-group>. <article-title>Prospective study of the impact of switching from an open IV infusion system to a closed system on rates of central venous catheter–associated bloodstream infection in a Brazilian hospital</article-title>. <conf-name>Presented at: Society for Healthcare Epidemiology of America 16th Annual Scientific Meeting</conf-name>; <conf-date>March 18-21, 2006</conf-date>; <conf-loc>Chicago, IL</conf-loc>.</citation>
</ref>
<ref id="bibr47-0148607111414714">
<label>47.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Tarricone</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Torbica</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Franzetti</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Hospital costs of central line–associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers: the case of intensive care units in Italy</article-title>. <source>Cost Eff Resour Alloc</source>. <year>2010</year>;<volume>8</volume>:<fpage>8</fpage>.</citation>
</ref>
<ref id="bibr48-0148607111414714">
<label>48.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Weaver</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Willy</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Avigan</surname><given-names>M</given-names></name>
</person-group>. <article-title>Informatic tools and approaches in postmarketing pharmacovigilance used by FDA</article-title>. <source>AAPS J</source>. <year>2008</year>;<volume>10</volume>:<fpage>35</fpage>-<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr49-0148607111414714">
<label>49.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Velentgas</surname><given-names>P</given-names></name>
<name name-style="western"><surname>West</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Cannuscio</surname><given-names>CC</given-names></name>
<name name-style="western"><surname>Watson</surname><given-names>DJ</given-names></name>
<name name-style="western"><surname>Walker</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2006</year>;<volume>15</volume>:<fpage>641</fpage>-<lpage>652</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>